Enclomiphene Citrate 7599-79-3 selective estrogen receptor antagonist
Payment: T/T, L/C
Product Origin: China
Shipping Port: Beijing/Shanghai/Hangzhou
Production capacity: 50kg/month
Order(MOQ): 1kg
Lead Time: 3 Working Days
Storage condition: Stored in cool and dry place, sealed and keep away from light.
Package material:vial, bottle
Package size:1kg/vial, 5kg/vial, 10kg/vial, 25kg/drum
Safety information: Not dangerous goods
Introduction
Enclomiphene is primarily used as a treatment for men with persistent low testosterone as a result of secondary hypogonadotropic hypogonadism. In secondary hypogonadotropic hypogonadism, the resulting low levels of testosterone is attributed to inadequacies in the hypothalamic-pituitary-gonadal axis. In contrast, primary hypogonadism is caused by defects in the testes that causes them to be unable to produce the required amount of testosterone.
Enclomiphene, which stimulates the endogenous production of testosterone, is not currently known to have common adverse effects of exogenous testosterone replacement therapy, such as reduced spermatogenesis or infertility.
Specification (in house standard)
|
Items |
Specifications |
|
Appearance |
White solid |
| Loss on drying | ≤0.5% |
| Residue on ignition | ≤0.1% |
| Heavy metals | ≤20ppm |
|
Z isomers |
≤1.0%, by HPLC |
|
Total impurities |
≤1.0%, by HPLC |
| Purity | ≥99.0% by HPLC |
